Debbie M Figueroa

Debbie M Figueroa

Auto-generated profile, based on publicly available information

Debbie M Figueroa

Department of Internal Medicine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Pharmacogenomics
Verified
Journal Article
Closed access
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
MWMax Weaver
Max Weaver
ASApril Schultz
April Schultz
DFDebbie M Figueroa
Debbie M Figueroa
KCKurt Christensen
Kurt Christensen
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.